Inmune Bio (INMB) Return on Capital Employed (2019 - 2025)
Historic Return on Capital Employed for Inmune Bio (INMB) over the last 6 years, with Q3 2025 value amounting to 1.82%.
- Inmune Bio's Return on Capital Employed fell 7500.0% to 1.82% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.82%, marking a year-over-year decrease of 7500.0%. This contributed to the annual value of 1.04% for FY2024, which is 4500.0% down from last year.
- According to the latest figures from Q3 2025, Inmune Bio's Return on Capital Employed is 1.82%, which was down 7500.0% from 1.93% recorded in Q2 2025.
- Inmune Bio's 5-year Return on Capital Employed high stood at 0.22% for Q2 2021, and its period low was 1.93% during Q2 2025.
- In the last 5 years, Inmune Bio's Return on Capital Employed had a median value of 0.44% in 2023 and averaged 0.73%.
- Its Return on Capital Employed has fluctuated over the past 5 years, first crashed by -500bps in 2023, then plummeted by -8400bps in 2025.
- Quarter analysis of 5 years shows Inmune Bio's Return on Capital Employed stood at 0.29% in 2021, then decreased by -23bps to 0.36% in 2022, then tumbled by -99bps to 0.72% in 2023, then crashed by -52bps to 1.09% in 2024, then tumbled by -67bps to 1.82% in 2025.
- Its last three reported values are 1.82% in Q3 2025, 1.93% for Q2 2025, and 1.35% during Q1 2025.